BACKGROUND: The antitumour immune response plays an important role in the prognosis of melanoma. High numbers of circulating regulatory T cells have been associated with rapid disease progression. OBJECTIVES: To assess the influence of forkhead box protein (FOXP)3, CD1a and langerin expression on the prognosis of primary melanoma. METHODS: We analysed 185 primary melanomas by immunohistochemical staining for expression of the regulatory T-cell marker FOXP3 and the dendritic cell markers langerin and CD1a, and correlated marker expression with clinical outcome. RESULTS: Disease-free survival and overall survival were significantly longer in patients expressing low levels of FOXP3 in the primary melanoma, whereas they were associated with high expression of CD1a. The negative prognostic value of FOXP3 expression was independent of the Breslow tumour thickness. Langerin expression did not correlate with the clinical outcome. CONCLUSIONS: High expression of FOXP3 in the primary melanoma may be used as an additional independent prognostic marker for early tumour progression in patients with melanoma.
BACKGROUND: The antitumour immune response plays an important role in the prognosis of melanoma. High numbers of circulating regulatory T cells have been associated with rapid disease progression. OBJECTIVES: To assess the influence of forkhead box protein (FOXP)3, CD1a and langerin expression on the prognosis of primary melanoma. METHODS: We analysed 185 primary melanomas by immunohistochemical staining for expression of the regulatory T-cell marker FOXP3 and the dendritic cell markers langerin and CD1a, and correlated marker expression with clinical outcome. RESULTS: Disease-free survival and overall survival were significantly longer in patients expressing low levels of FOXP3 in the primary melanoma, whereas they were associated with high expression of CD1a. The negative prognostic value of FOXP3 expression was independent of the Breslow tumour thickness. Langerin expression did not correlate with the clinical outcome. CONCLUSIONS: High expression of FOXP3 in the primary melanoma may be used as an additional independent prognostic marker for early tumour progression in patients with melanoma.
Authors: Sarah A Weiss; Sung Won Han; Kevin Lui; Jeremy Tchack; Richard Shapiro; Russell Berman; Judy Zhong; Michelle Krogsgaard; Iman Osman; Farbod Darvishian Journal: Hum Pathol Date: 2016-07-26 Impact factor: 3.466
Authors: Sita S Withers; Katherine A Skorupski; Daniel York; Jin W Choi; Kevin D Woolard; Renee Laufer-Amorim; Ellen E Sparger; Carlos O Rodriguez; Stephen J McSorley; Arta M Monjazeb; William J Murphy; Robert J Canter; Robert B Rebhun Journal: Vet Comp Oncol Date: 2018-09-19 Impact factor: 2.613
Authors: Pedro A C Costa; Walison N Silva; Pedro H D M Prazeres; Caroline C Picoli; Gabriela D A Guardia; Alinne C Costa; Mariana A Oliveira; Pedro P G Guimarães; Ricardo Gonçalves; Mauro C X Pinto; Jaime H Amorim; Vasco A C Azevedo; Rodrigo R Resende; Remo C Russo; Thiago M Cunha; Pedro A F Galante; Akiva Mintz; Alexander Birbrair Journal: Acta Neuropathol Commun Date: 2021-11-16 Impact factor: 7.801
Authors: Beatriz G S Rocha; Caroline C Picoli; Bryan O P Gonçalves; Walison N Silva; Alinne C Costa; Michele M Moraes; Pedro A C Costa; Gabryella S P Santos; Milla R Almeida; Luciana M Silva; Youvika Singh; Marcelo Falchetti; Gabriela D A Guardia; Pedro P G Guimarães; Remo C Russo; Rodrigo R Resende; Mauro C X Pinto; Jaime H Amorim; Vasco A C Azevedo; Alexandre Kanashiro; Helder I Nakaya; Edroaldo L Rocha; Pedro A F Galante; Akiva Mintz; Paul S Frenette; Alexander Birbrair Journal: Angiogenesis Date: 2022-10-01 Impact factor: 10.658
Authors: Satu Salmi; Anton Lin; Benjamin Hirschovits-Gerz; Mari Valkonen; Niina Aaltonen; Reijo Sironen; Hanna Siiskonen; Sanna Pasonen-Seppänen Journal: BMC Cancer Date: 2021-05-29 Impact factor: 4.430